Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B.
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2015
At a glance
- Drugs Poziotinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Hanmi Pharmaceutical
- 12 Dec 2015 Pooled analysis of 2 trials including this study and another study [see CTP 700208665] were presented at the 38th Annual San Antonio Breast Cancer Symposium.
- 25 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Apr 2013 Planned End Date changed from 1 Jul 2012 to 1 May 2013 as reported by ClinicalTrials.gov.